SCM
SNDX icon

Soleus Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Soleus Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.6M Sell
1,628,039
-98,869
-6% -$2.06M 1.23% 23
2026
Q1 		$40.3M Sell
1,726,908
-520,202
-23% -$11.3M 1.63% 17
2025
Q4 		$47.2M Buy
2,247,110
+235,000
+12% +$4.1M 1.74% 14
2025
Q3 		$31M Buy
2,012,110
+920,000
+84% +$12M 1.56% 21
2025
Q2 		$10.2M Buy
1,092,110
+275,500
+34% +$3.03M 0.68% 38
2025
Q1 		$10M Sell
816,610
-1,675,390
-67% -$23.6M 0.72% 37
2024
Q4 		$32.9M Buy
2,492,000
+1,401,016
+128% +$24M 2.07% 15
2024
Q3 		$21M Buy
1,090,984
+264,484
+32% +$5.46M 1.63% 20
2024
Q2 		$17M Buy
826,500
+457,500
+124% +$9.57M 1.5% 26
2024
Q1 		$8.78M Sell
369,000
-145,000
-28% -$3.23M 0.65% 47
2023
Q4 		$11.1M Buy
514,000
+394,500
+330% +$6.06M 1.23% 26
2023
Q3 		$1.74M Sell
119,500
-93,100
-44% -$1.76M 0.16% 71
2023
Q2 		$4.45M Sell
212,600
-110,000
-34% -$2.29M 0.49% 51
2023
Q1 		$6.81M Buy
322,600
+102,600
+47% +$2.55M 0.71% 41
2022
Q4 		$5.6M Buy
+220,000
New +$5.13M 0.8% 36
2020
Q2 		– Sell
-20,980
Closed -$230K – 68
2020
Q1 		$230K Hold
20,980
– – 0.27% 42
2019
Q4 		$184K Buy
+20,980
New +$154K 0.18% 49

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Soleus Capital Management's SNDX Position: Q2 2026 in Review

Soleus Capital Management reduced its Syndax Pharmaceuticals (SNDX) stake by 5.7% in Q2 2026, selling an estimated $2.06M and leaving 1,628,039 shares worth $35.6M. The position accounts for 1.23% of the portfolio, ranked #23.

Soleus Capital Management first reported a position in SNDX in Q4 2019 and has held it in 17 quarters since. The position peaked at $47.2M in Q4 2025. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Soleus Capital Management held 1,628,039 shares of Syndax Pharmaceuticals worth $35.6M as of Q2 2026.
  • Soleus Capital Management sold 98,869 Syndax Pharmaceuticals shares in Q2 2026, an estimated $2.06M.
  • Syndax Pharmaceuticals made up 1.23% of Soleus Capital Management's portfolio in Q2 2026, its #23 holding.
  • Soleus Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2019 and has held it in 17 quarters since.
  • Soleus Capital Management's Syndax Pharmaceuticals position peaked at $47.2M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.